Log in

NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, Forecast & News

$48.24
-11.08 (-18.68 %)
(As of 02/28/2020 07:07 AM ET)
Today's Range
$47.10
Now: $48.25
$56.93
50-Day Range
$48.25
MA: $61.56
$67.14
52-Week Range
$47.10
Now: $48.25
$86.96
Volume193,574 shs
Average Volume58,208 shs
Market Capitalization$583.28 million
P/E Ratio35.74
Dividend YieldN/A
Beta1.98
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANIP
Previous SymbolNASDAQ:BPAX
CUSIPN/A
Phone218-634-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.58 million
Cash Flow$6.04 per share
Book Value$16.63 per share

Profitability

Net Income$15.49 million

Miscellaneous

Employees299
Market Cap$583.28 million
Next Earnings DateN/A
OptionableOptionable

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.


ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its earnings results on Thursday, February, 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.18 by $0.10. The specialty pharmaceutical company had revenue of $47.97 million for the quarter, compared to analysts' expectations of $51.63 million. ANI Pharmaceuticals had a net margin of 7.58% and a return on equity of 28.28%. The business's revenue was down 16.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.32 earnings per share. View ANI Pharmaceuticals' Earnings History.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided earnings per share (EPS) guidance of 4.46-4.86 for the period, compared to the Thomson Reuters consensus estimate of $5.47. The company issued revenue guidance of $213-223 million, compared to the consensus revenue estimate of $229.15 million.

What price target have analysts set for ANIP?

4 analysts have issued 12 month price targets for ANI Pharmaceuticals' stock. Their forecasts range from $76.00 to $90.00. On average, they expect ANI Pharmaceuticals' stock price to reach $84.25 in the next year. This suggests a possible upside of 74.6% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

What is the consensus analysts' recommendation for ANI Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

Has ANI Pharmaceuticals been receiving favorable news coverage?

Headlines about ANIP stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for ANI Pharmaceuticals.

Who are some of ANI Pharmaceuticals' key competitors?

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Broadcom (AVGO), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Cisco Systems (CSCO), NXP Semiconductors (NXPI) and Skyworks Solutions (SWKS).

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:
  • Mr. Arthur S. Przybyl, Pres, CEO & Director (Age 62)
  • Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47)

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.56%), Investment Counselors of Maryland LLC (2.35%), Goldman Sachs Group Inc. (2.31%), Renaissance Technologies LLC (2.20%), Hawk Ridge Capital Management LP (1.56%) and Global Alpha Capital Management Ltd. (1.40%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

Which major investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Renaissance Technologies LLC, Mackay Shields LLC, SG Americas Securities LLC, LSV Asset Management, Chicago Equity Partners LLC and Perkins Capital Management Inc.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

Which major investors are buying ANI Pharmaceuticals stock?

ANIP stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Hawk Ridge Capital Management LP, California Public Employees Retirement System, Man Group plc, Acadian Asset Management LLC, Global Alpha Capital Management Ltd., First Trust Advisors LP and Russell Investments Group Ltd.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $48.25.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $583.28 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]


MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  390 (Thanks for Voting!)
Underperform Votes:  355 (Thanks for Voting!)
Total Votes:  745
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel